cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Exelixis Inc
22 own
35 watching
Current Price
$35.82
$-0.22
(-0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,174.08M
52-Week High
52-Week High
36.97000
52-Week Low
52-Week Low
19.20000
Average Volume
Average Volume
1.36M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
37.9484
iconMarket Capitalization7,174.08M
icon52-Week High36.97000
icon52-Week Low19.20000
iconAverage Volume1.36M
iconDividend Yield--
iconP/E Ratio37.9484
What does the Exelixis Inc do?
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Read More
How much money does Exelixis Inc make?
News & Events about Exelixis Inc.
TipRanks Financial Blog
1 year ago
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Exelixis (EXEL Research Report) yesterday and set a price target of ... Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Exelixis (EXEL Re...
Zolmax
1 year ago
Deutsche Bank AG grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL Get Rating) by 3.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,550,060 shares of the biotechnology companys stock after purchasing an additional 91,086 shares during the period. ...
Business Wire
1 year ago
Funds managed by Farallon Capital Management, L.L.C. (Farallon) own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (Exelixis or the Company), making it the Companys largest active shareholder. Today, Farallon filed definitive proxy materials in connection with...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL Research Report). The companys sha... In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Sell rating on Exelixis (EXEL &#8211...
Zolmax
1 year ago
StockNews.com upgraded shares of Exelixis (NASDAQ:EXEL Get Rating) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. EXEL has been the topic of several other research reports. EF Hutton Acquisition Co. I reaffirmed a buy rating and issued a $24.00 price ...
Frequently Asked Questions
Frequently Asked Questions
What is Exelixis Inc share price today?
plus_minus_icon
Can Indians buy Exelixis Inc shares?
plus_minus_icon
How can I buy Exelixis Inc shares from India?
plus_minus_icon
Can Fractional shares of Exelixis Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Exelixis Inc stocks?
plus_minus_icon
What is today’s traded volume of Exelixis Inc?
plus_minus_icon
What is today’s market capitalisation of Exelixis Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Exelixis Inc?
plus_minus_icon
What percentage is Exelixis Inc down from its 52-Week High?
plus_minus_icon
What percentage is Exelixis Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$35.82
$-0.22
(-0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
MOLECULAR TEMPLATES INC
MOLECULAR TEMPLATES INC
$0.42
$-0.12 (-22.22 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.66
$-0.02 (-2.37 %)
DBV Technologies S.A. - Spons-ADR
DBV Technologies S.A. - Spons-ADR
$3.66
$0.00 (0.00 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$133.00
$0.93 (0.70 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
MOLECULAR TEMPLATES INC
MOLECULAR TEMPLATES INC
$0.42
$-0.12 (-22.22 %)
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.66
$-0.02 (-2.37 %)
DBV Technologies S.A. - Spons-ADR
DBV Technologies S.A. - Spons-ADR
$3.66
$0.00 (0.00 %)
Ascendis Pharma A/S
Ascendis Pharma A/S
$133.00
$0.93 (0.70 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00